Src inhibitor

Src inhibitor is a class of inhibitors that targets src kinase family of tyrosine kinases, which is transcribed by proto-oncogenes src genes (abbreviating for sarcome genes) that potentially induced cell of malignant transformation. Because of the crucial position of src gene/kinase in cells, src inhibitors are potential antineoplastic agents for pancreatic cancer, breast cancer, stomach cancer etc.[1]

chemical structure of KX2-391

Examples

  • KX2-391 is an oral src inhibitor and the first clinical inhibitor with GI50 of 9–60 nM in cancer cell lines.[2]
  • Bosutinib has been developed for the treatment of chronic myelogenous leukemia by Pfizer.
  • Saracatinib, the first Src inhibitor to show inhibition of the Src pathway in human tumor tissue, has anti-tumor activity alone or in combination with chemotherapeutic agents.[3]
chemical structure of PP1

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.